KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Invested Capital (2016 - 2025)

Arbutus Biopharma's Invested Capital history spans 16 years, with the latest figure at $77.4 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 27.59% year-over-year to $77.4 million; the TTM value through Sep 2025 reached $77.4 million, down 27.59%, while the annual FY2024 figure was $97.4 million, 8.16% down from the prior year.
  • Invested Capital for Q3 2025 was $77.4 million at Arbutus Biopharma, down from $83.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $169.4 million in Q4 2021 and bottomed at $77.4 million in Q3 2025.
  • The 5-year median for Invested Capital is $119.3 million (2023), against an average of $121.1 million.
  • The largest annual shift saw Invested Capital soared 66.17% in 2021 before it tumbled 32.24% in 2025.
  • A 5-year view of Invested Capital shows it stood at $169.4 million in 2021, then dropped by 19.23% to $136.9 million in 2022, then decreased by 22.53% to $106.0 million in 2023, then dropped by 8.16% to $97.4 million in 2024, then fell by 20.51% to $77.4 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Invested Capital are $77.4 million (Q3 2025), $83.0 million (Q2 2025), and $79.2 million (Q1 2025).